Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Lindgren

Showing results (71-80 of 163) with videos related to

Pageof 17
Sort By:
Muscle & Nerve|February 22, 2018
Psychometric analysis of the pediatric quality of life inventory 3.0 neuromuscular module administered to patients with duchenne muscular dystrophy: A rasch analysisErik Landfeldt, Anna Mayhew, Volker Straub, et al.
European Heart Journal|March 21, 2007
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatinPeter Lindgren, Jennifer Graff, Anders G Olsson, et al.
European Journal of Internal Medicine|December 28, 2012
Long term health care consumption and cost expenditure in systolic heart failureMärit Mejhert, Peter Lindgren, Owe Schill, et al.
Lakartidningen|June 1, 2016
[NIPT is a breakthrough in prenatal diagnostics]Bo Jacobsson, Christian Munthe, Sissel Saltvedt, et al.
BMC Pregnancy and Childbirth|February 24, 2021
Reference ranges of fetal superior vena cava blood flow velocities and pulsatility index in the second half of pregnancy: a longitudinal studyMaria Stefopoulou, Lotta Herling, Jonas Johnson, et al.
Frontiers in Pediatrics|July 23, 2021
Fetal Superior Vena Cava Blood Flow and Its Fraction of Cardiac Output: A Longitudinal Ultrasound Study in the Second Half of PregnancyMaria Stefopoulou, Jonas Johnson, Lotta Herling, et al.
JAMA Cardiology|June 6, 2019
Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular DiseaseGregg C Fonarow, Ben van Hout, Guillermo Villa, et al.
Pharmacoeconomics|November 1, 2016
Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness AnalysisErik Landfeldt, Lars Alfredsson, Volker Straub, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 21, 2015
Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure RegistryJenny Berg, Peter Lindgren, Märit Mejhert, et al.
Lakartidningen|July 5, 2017
Peter Lindgren, Charlotta Ingvoldstad Malmgren, Niklas Juth, et al.
Pageof 17

Showing results (71-80 of 163) with videos related to

Sort By:
Pageof 17
Muscle & Nerve|February 22, 2018
Psychometric analysis of the pediatric quality of life inventory 3.0 neuromuscular module administered to patients with duchenne muscular dystrophy: A rasch analysisErik Landfeldt, Anna Mayhew, Volker Straub, et al.
European Heart Journal|March 21, 2007
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatinPeter Lindgren, Jennifer Graff, Anders G Olsson, et al.
European Journal of Internal Medicine|December 28, 2012
Long term health care consumption and cost expenditure in systolic heart failureMärit Mejhert, Peter Lindgren, Owe Schill, et al.
Lakartidningen|June 1, 2016
[NIPT is a breakthrough in prenatal diagnostics]Bo Jacobsson, Christian Munthe, Sissel Saltvedt, et al.
BMC Pregnancy and Childbirth|February 24, 2021
Reference ranges of fetal superior vena cava blood flow velocities and pulsatility index in the second half of pregnancy: a longitudinal studyMaria Stefopoulou, Lotta Herling, Jonas Johnson, et al.
Frontiers in Pediatrics|July 23, 2021
Fetal Superior Vena Cava Blood Flow and Its Fraction of Cardiac Output: A Longitudinal Ultrasound Study in the Second Half of PregnancyMaria Stefopoulou, Jonas Johnson, Lotta Herling, et al.
JAMA Cardiology|June 6, 2019
Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular DiseaseGregg C Fonarow, Ben van Hout, Guillermo Villa, et al.
Pharmacoeconomics|November 1, 2016
Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness AnalysisErik Landfeldt, Lars Alfredsson, Volker Straub, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 21, 2015
Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure RegistryJenny Berg, Peter Lindgren, Märit Mejhert, et al.
Lakartidningen|July 5, 2017
Peter Lindgren, Charlotta Ingvoldstad Malmgren, Niklas Juth, et al.
Pageof 17